Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 02 10 2019
accepted: 08 11 2019
pubmed: 10 1 2020
medline: 27 10 2020
entrez: 10 1 2020
Statut: ppublish

Résumé

Although typically arranged in solid alveolar fashion, chromophobe renal cell carcinoma (RCC) may also show several other architectural growth patterns. We include in this series 8 chromophobe RCC cases with prominent papillary growth, a pattern very rarely reported or only mentioned as a feature of chromophobe RCC, which is lacking wider recognition The differential diagnosis of such cases significantly varies from the typical chromophobe RCC with its usual morphology, particularly its distinction from papillary RCC and other relevant and clinically important entities. Of 972 chromophobe RCCs in our files, we identified 8 chromophobe RCCs with papillary growth. We performed immunohistochemistry and array Comparative Genomic Hybridisation (aCGH) to investigate for possible chromosomal aberrations. Patients were 3 males and 5 females with age ranging from 30 to 84 years (mean 57.5, median 60 years). Tumor size was variable and ranged from 2 to 14 cm (mean 7.5, median 6.6 cm). Follow-up was available for 7 of 8 patients, ranging from 1 to 61 months (mean 20.1, median 12 months). Six patients were alive with no signs of aggressive behavior, and one died of the disease. Histologically, all cases were composed of dual cell population consisting of variable proportions of leaf-like cells with pale cytoplasm and eosinophilic cells. The extent of papillary component ranged from 15 to 100% of the tumor volume (mean 51%, median 50%). Sarcomatoid differentiation was identified only in the case with fatal outcome. Immunohistochemically, all tumors were positive for CK7, CD117 and Hale's Colloidal Iron. PAX8 was positive in 5 of 8 cases, TFE3 was focally positive 3 of 8 tumors, and Cathepsin K was focally positive in 2 of 8 tumors. All cases were negative for vimentin, AMACR and HMB45. Fumarate hydratase staining was retained in all tested cases. The proliferative activity was low (up to 1% in 7, up to 5% in one case). Three cases were successfully analyzed by aCGH and all showed a variable copy number variation profile with multiple chromosomal gains and losses. CONCLUSIONS: Chromophobe RCC demonstrating papillary architecture is an exceptionally rare carcinoma. The diagnosis can be challenging, although the cytologic features are consistent with the classic chromophobe RCC. Given the prognostic and therapeutic implications of accurately diagnosis other RCCs with papillary architecture (i.e., Xp11.2 translocation RCC, FH-deficient RCC), it is crucial to differentiate these cases from chromophobe RCC with papillary architecture. Based on this limited series, the presence of papillary architecture does not appear to have negative prognostic impact. However, its wider recognition may allow in depth studies on additional examples of this rare morphologic variant.

Identifiants

pubmed: 31918172
pii: S1092-9134(19)30377-6
doi: 10.1016/j.anndiagpath.2019.151448
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151448

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare no conflict of interest.

Auteurs

Kvetoslava Michalova (K)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Maria Tretiakova (M)

Department of Pathology, University of Washington, Seattle, WA, USA.

Kristyna Pivovarcikova (K)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Reza Alaghehbandan (R)

Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

Delia Perez Montiel (D)

Department of Pathology, Institute Nacional de Cancerologia, Mexico City, Mexico.

Monika Ulamec (M)

Ljudevit Jurak Pathology Department, University Clinical Hospital "Sestre milosrdnice", Pathology Department, School of Dental Medicine, University of Zagreb, Croatia.

Adeboye Osunkoya (A)

Department of Pathology, Emory Hospital, Atlanta, USA.

Kiril Trpkov (K)

Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada.

Gao Yuan (G)

Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada.

Petr Grossmann (P)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Maris Sperga (M)

Department of Pathology, University of Split, Croatia.

Ivan Ferak (I)

Department of Pathology, AGEL, Novy Jicin, Czech Republic.

Joanna Rogala (J)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Jana Mareckova (J)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Tomas Pitra (T)

Department of Urology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Jiri Kolar (J)

Department of Urology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Michal Michal (M)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

Ondrej Hes (O)

Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic. Electronic address: hes@medima.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH